The pandemic has eased throughout much of the world. But demand for COVID-19 vaccines and treatments continues to be brisk, according to ratings agency Moody’s. In general, the pandemic will contribute to the pharmaceutical industry’s projected EBITDA growth rate of 4% to 6% over the coming 12 to 18 months, the firm concluded.
While a significant number of vaccines and antivirals are already in use, more will likely win regulatory authorization in the coming months. But the volume of future COVID-19 therapy sales will hinge upon “how the pandemic evolves,” the Moody’s report acknowledged.
Other factors driving growth include growing healthcare use as countries such as the U.S. continue to lift COVID-19 restrictions.
Oncology, one of the most rapidly growing pharma areas, is likely to continue its growth trajectory. Moody’s expects immuno-onco…